^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CS5001

    i
    Other names: CS5001, ABL202, LCB71, ABL 202
    Company:
    ABL Bio, CStone Pharma, LigaChem Biosci
    Drug class:
    DNA replication inhibitor, ROR1-targeted antibody-drug conjugate
    Related drugs:
    1year
    A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas (clinicaltrials.gov)
    P1, N=156, Recruiting, CStone Pharmaceuticals | Trial completion date: Mar 2024 --> Jun 2025
    Trial completion date
    |
    CS5001
    3years
    [VIRTUAL] CS5001, a novel ROR1-targeting antibody drug conjugate (ADC) armed with tumor- cleavable β-glucuronide linkers and pyrrolobenzodiazepine (PBD) prodrugs for hematological and solid malignancies (AACR-NCI-EORTC 2021)
    No abstract available
    Late-breaking abstract
    |
    ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1)
    |
    CS5001